Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24252
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKapetanos, D.en
dc.contributor.authorKokozidis, G.en
dc.contributor.authorChristodoulou, D.en
dc.contributor.authorMistakidis, K.en
dc.contributor.authorSigounas, D.en
dc.contributor.authorDimakopoulos, K.en
dc.contributor.authorKitis, G.en
dc.contributor.authorTsianos, E. V.en
dc.date.accessioned2015-11-24T19:39:30Z-
dc.date.available2015-11-24T19:39:30Z-
dc.identifier.issn0016-5107-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24252-
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectBile Duct Diseases/diagnosis/*therapyen
dc.subjectCholangiopancreatography, Endoscopic Retrograde/*adverse effectsen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectHyperamylasemia/prevention & controlen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPancreatitis/*prevention & controlen
dc.subjectPentoxifylline/*therapeutic useen
dc.subject*Premedicationen
dc.subjectSphincterotomy, Endoscopic/adverse effectsen
dc.titleA randomized controlled trial of pentoxifylline for the prevention of post-ERCP pancreatitisen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1016/j.gie.2007.03.1045-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17725940-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0016510707015805/1-s2.0-S0016510707015805-main.pdf?_tid=ab6c1fd6edfcde3f1f39b3c11468c003&acdnat=1333960569_2aed7b37ad32fa51bb88d35594ab8156-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2007-
heal.abstractBACKGROUND: Pentoxifylline can ameliorate pancreatitis in animal models because of its anti-tumor necrosis factor properties. OBJECTIVE: Our purpose was to study the safety and efficacy of pentoxifylline in the prevention of post-ERCP pancreatitis. DESIGN: Patients due to undergo ERCP for various indications were randomized to receive pentoxifylline 400 mg orally 3 times, beginning the day before ERCP (2 and 10 pm) until the night after the procedure (6 am and 2 and 10 pm) or to receive no preventive medication. Serum amylase values were determined before and 6 and 24 hours after ERCP. Diagnosis and grading of the severity of complications was performed according to consensus criteria. PATIENTS: One hundred fifty-eight patients received pentoxifylline (group A) and 162 had no medication (group B). The groups were similar in distributions of sex, biliary sphincterotomy, pancreatography, pancreatic duct cannulations, stone extraction, stent placement, and presence of periampullary diverticulum. Group A patients were younger (mean age 63 vs 68 years, P<.05) and biliary colic was a more frequent indication (30 vs 12, P<.05). RESULTS: Nine (5.6%) patients in group A and 5 (3%) in group B had pancreatitis (2 and 1 severe, respectively; P=.28). Serum amylase values were similar in baseline and 6- and 24-hour samples. Two (1.2%) patients in group A and 7 (4.3%) in group B had hemorrhage. LIMITATIONS: This was not a double-blind trial. CONCLUSIONS: In this study pentoxifylline did not protect against post-ERCP pancreatitis or hyperamylasemia.en
heal.journalNameGastrointest Endoscen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Kapetanos-2007-A randomized control.pdf188 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons